+++ Eisbach receives IND clearance for lead candidate EIS-12656, a first-in-class allosteric inhibitor of ALC1, from the FDA ++++++ Insempra completes $20 million financing to advance the development of next-generation bio-based ingredients. ++++++ Tubulis presents novel preclinical data for its lead ADC candidates targeting solid tumors at AACR 2024 ++++++ Eisbach receives USD 4.5 million investment from Cancer Focus Fund to support Phase 1/2 trial of lead candidate EIS-12656 ++++++ Tubulis secures significant EUR 128 million Series B2 financing ++++++ Novel small molecule drugs of the future targeting the CNS ++++++ Christian Gnam succeeds Dr. Peter Zobel as new Managing Director of the Biotechnology Innovation and Start-up Center (IZB) ++++++ Thermosome advances Phase I trial with lead candidate THE001 to next dose level ++++++ MorphoSys enters into Business Combination Agreement to be Acquired by medicines company Novartis ++++++ CatalYm strengthens Board of Directors and Scientific Advisory Board with key appointments ++++++ Tubulis out-licenses IND-ready ADC for the treatment of lymphoma to Oncoteq ++++++ MorphoSys ends the year with positive phase 3 data and successful cash capital increase of approximately EUR 102.7 million ++++++ Oncology experts to support the development of Thermosome’s clinical candidate THE001 ++++++ Renowned Peutinger-Collegium visits the IZB ++++++ SciRhom submits clinical trial application for first-in-human trials with lead candidate SR-878 ++++++ GoingPublic celebrates a quarter century of biotech ++++++ 4SC’s resminostat receives Orphan Drug Designation from the European Medicines Agency ++++++ Dr. Peter Hanns Zobel, CEO of IZB, Bids Farewell ++++++ Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology ++++++ High-Profile Clinical Advisory Board for Thermosome ++++++ Successful Economic Reception at IZB with Dr. Theo Waigel, Former Federal Minister of Finance, as Guest Speaker ++++++ MorphoSys’ program tulmimetostat receives FDA Fast Track designation ++++++ adivo becomes part of the world’s leading animal health company Zoetis ++++++ The Munich Bavaria Student Union visits the IZB ++++++ Bind-X secures €10 million in financing as part of its Series B financing round ++++++ Biotech Companies from Munich’s start-up center IZB convince prominent partners with excellent research ++++++ 23 students from Europe visited the IZB as part of the AMGEN Scholar Program ++++++ M1 – Munich Medical Alliance: Becoming Germany’s No. 1 medical hub ++++++ Neutralizing GDF-15: Development of a new class of anti-cancer immunotherapy ++++++ Vivoryon Therapeutics highlights progress of lead candidate varoglutamstat in Alzheimer’s disease ++++++ leon-nanodrugs welcomes Dr. Hans Frickel as new CEO ++++++ Pioneering research projects at the 8th Life Science Pitch Day at the IZB ++++++ Japanese delegation visits the IZB ++++++ Bavarian biotechnology maintains its position in the crisis and continues to grow ++++++ Biotech company Origenis welcomes Prof. Hendrik Liebers as Chairman of the Board ++++++ Official handover ceremony at the Annual Meeting of the Max Planck Society ++++++ Secarna appoints new Chief Business Officer ++++++ Bicoll showcases at BIO International Convention ++++++ Thermosome joins IMAGIO consortium to advance development of cancer therapies for soft tissue sarcoma ++++++ Breakthrough in fluorescence microscopy at the Max Planck Institute of Biochemistry ++++++ New preclinical data show long-term antitumor effects of Secarna Pharmaceuticals’ antisense oligonucleotide (ASO) therapies ++++++ Biotech report by vfa: Biopharmaceuticals successfully gain market share ++++++ Preclinical efficacy and safety data for ViGeneron’s innovative approach to the treatment of Retinitis Pigmentosa ++++++ MPI of Biochemistry: Nature publication addressing the “dark matter” of proteomics ++++++ Non-nutritive sweeteners may affect the human immune system ++++++ LMU Hospital’s annual reception returned this year with exciting topics and a multimedia “magic show” ++++++ Invitris receives 250,000 EUR to complete spin-out from TUM ++++++ Eisbach starts phase I clinical trial with COVID-19 antiviral ++++++ IZB Connects with Shanghai Zhangjiang Hi-Tech Park ++++++ Specific packaging of DNA affects cell division ++++++ Tubulis Enters Strategic Partnership with BMS ++++++ Insempra launches its first functional component for consumer goods ++++++ ERC Advanced Grant of nearly 2.1 million euros for Prof. Dr. Brenda Schulman ++++++ Vivoryon Therapeutics gives update on clinical development of its lead candidate against Alzheimer’s Disease ++++++ Secarna Pharmaceuticals and SciNeuro Pharmaceuticals form partnership ++++++ adivo expands into new headquarters as first clinical study begins ++++++ Thermosome’s Lead Program THE001 receives regulatory approval for first-in-human trial ++++++ Construction of the “New Hauner” at the Grosshadern Campus has started ++++++ Insempra names new Chief Operating Officer ++++++ Training events for project managers and biological safety officers ++++++ The zebrafish brain as a map ++++++ MorphoSys stops proprietary pre-clinical research programs and further optimizes cost structure ++++++ Innovation and Start-up Center Biotechnology (IZB) welcomes Invitris ++++++ When life begins too early ++++++ US-based Neuron23 starts Phase 1 clinical trial in Parkinson’s Disease ++++++ Expansion of the Munich “science line” has started ++++++ Enno Spillner to join Formycon as CFO +++
